New Zealand markets close in 9 minutes

OCGN Jan 2025 5.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.2000-0.0500 (-20.00%)
As of 03:12PM EST. Market open.
Full screen
Previous close0.2500
Open0.2500
Bid0.1000
Ask0.2500
Strike5.00
Expiry date2025-01-17
Day's range0.2000 - 0.2800
Contract rangeN/A
Volume37
Open interest4.21k
  • GlobeNewswire

    Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

    MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the Abu Dhabi Family Office (ADFO) Summit being held February 29—March 1, 2024 at the Saadiyat Rotana Resort and Villas in Abu Dhabi, United Arab Emirate

  • GlobeNewswire

    Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

    MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease is an orphan blindness disease that affects approximat

  • GlobeNewswire

    Ocugen to Present at 2024 BIO CEO & Investor Conference

    MALVERN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 26-27, 2024, at the Marriott Marquis in New York City. Members of Ocugen’s leadership team will con